Suggestions
Waleed Shalaby, MD PhD
Vice President Medical Affairs and Clinical Science-Oncology
Waleed Shalaby, MD PhD, is the Vice President of Medical Affairs and Clinical Science-Oncology at Galvanize Therapeutics, Inc. He has a rich background in oncology and medical affairs, particularly focused on advancing cancer patient care.
Educational Background
- Bachelor of Science in Chemistry: Purdue University (1984-1988)
- Doctor of Philosophy in Pharmaceutical Sciences: Purdue University (1988-1992)
- Doctor of Medicine: Medical University of South Carolina (1992-1996)
- Residency in Obstetrics and Gynecology: University of Pennsylvania (1996-2000)
- Fellowship in Gynecologic Oncology: University of Pennsylvania (2000-2003)
Professional Experience
Dr. Shalaby has held various significant roles throughout his career:
- Vice President of Medical Affairs and Clinical Science-Oncology at Galvanize Therapeutics, Inc.
- Executive Medical Director and Therapeutic Area Lead-Oncology at Daiichi Sankyo, Inc.
- Senior Medical Director of Clinical Development at Novocure.
- Director of Medical Affairs Oncology at Janssen Pharmaceuticals.
- Senior Medical Director of Women's Health at AMAG Pharmaceuticals.
Additionally, he has served as a Robotic Surgery Proctor at Intuitive and is an Adjunct Assistant Professor of Bioengineering at Clemson University. His previous role as Chief Science Officer at Poly-Med, Inc. involved providing insights for the development of absorbable polymeric systems for surgical applications.
Contributions and Focus
Dr. Shalaby is dedicated to improving outcomes for cancer patients through innovative medical practices and research. His work involves collaboration across various sectors within the pharmaceutical industry, focusing on areas such as gynecologic oncology and robotic-assisted surgery. He has also been involved in clinical trials and has a strong emphasis on developing new treatment modalities for solid tumors.
His commitment to cancer care is evident in his extensive experience and contributions to both clinical practice and medical education.12
Highlights
I am very exciting to start a new position as Executive Medical Director, Therapeutic Area Lead-Oncology, US Medical Affairs at Daiichi Sankyo, Inc. As I consider this my second "residency/fellowship", I truly appreciate the training afforded to me at NOVOCURE and the opportunity to hopefully allow TTFields to become a clinical reality for platinum-resistant ovarian cancer patients. To my new colleagues at DSI, looking forwarded to the journey of translating this innovative pipeline into clinically impactful options for cancer patients. In the words of the late Dr. Paul Janssen..."the patients are waiting" and there is always that sense of urgency.
